To evaluate the efficacy of tacrolimus for prevention of graft-versus-host disease (GVHD) in patients receiving allogeneic bone marrow transplants.
DATA SOURCES:
Published literature was identified through MEDLINE (January 1990–December 1998) using the key words tacrolimus, FK506, graft-versus-host disease, and bone marrow transplant.
DATA SYNTHESIS:
GVHD associated with allogeneic bone marrow transplant is a serious life-threatening complication. An evaluation of studies using tacrolimus for prevention of GVHD was conducted.
CONCLUSIONS:
Tacrolimus is effective for the prevention of GVHD in allogeneic bone marrow transplant. Further studies need to be conducted to optimize the dosage schedule and to determine therapeutic ranges, efficacy, and safety.
ShepherdJDShoreTBReeceDEBarnettMJKlingemannHGBuskardNACyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant1988;3: 553–8.
2.
BeattyPGHansenJALongtonGMThomasEDSandersJEMartinPJMarrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation1991;51: 443–7.
3.
SchwinghammerTLBloomELRosenfeldCSWilsonJWPrzepiorkaDShadduckRK. High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease. Bone Marrow Transplant1995;16:147–54.
4.
StorbRDeegJWhiteheadJAppelbaumFBeattyPBensingerWMethotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med1986;314:729–35.
5.
MrsicMLabarBBogdanicVNemetDPavleticZPlavsicFCombination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant1990;6:137–41.
KellyPABurckartGJVenkataramananR. Tacrolimus: A new immunosuppressive agent. Am J Health Syst Pharm1995;52:1521–35.
8.
BlazarBRTaylorPAFitzsimmonsWEValleraDA. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. J Immunol1994;153: 1836–46.
9.
StorbRRaffRFAppelbaumFRDeegHJFitzsimmonsWGrahamTCFK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen—nonidentical donors. Transplantation1993;56: 800–7.
10.
NashRAEtzioniRStorbRFurlongTGooleyTAnasettiCTacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study. Blood1995;85:3746–53.
11.
FayJWWingardJRAntinJHCollinsRHPineiroLABlazarBRFK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood1996;87:3514–9.
12.
UbertiJPSilverSMAdamsPTJacobsonPScalzoARatanatharathornV. Tacrolimus and methotrexate for the prophylaxis of acute graft-ver-sus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Bone Marrow Transplant1997;19: 1233–8.
13.
PrzepiorkaDIppolitiCKhouriIAnderliniPMehraRGiraltSAllogeneic transplantation for advanced leukemia. Transplantation1996;62:1806–10.
14.
RatanatharathornVNashRAPrzepiorkaDDevineSMKleinJLWeisdorfDPhase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood1998;92:2303–14.
15.
NashRAPineiroLAStorbRDeegHJFitzsimmonsWEFurlongTFK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood1996;88:3634–41.
16.
PrzepiorkaDIppolitiCKhouriIWooMMehraRLe BherzDTacrolimus and mini-dose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood1996;88:4383–9.
